Recently, EGFRM+ NSCLC patients with low expression level of the transcriptional BIM-inducer Human antigen R (HuR) were reported to display reduced BIM expression, intrinsic resistance to EGFR-TKIs, and significantly shortened PFS, while ectopic overexpression of HuR was able to enhance sensitivity to gefitinib in NSCLC cells in vitro and in vivo [226]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.